Your session is about to expire
← Back to Search
Reduced-Dose Chemotherapy for Lung Cancer
Study Summary
This trial will measure how well chemotherapy works in lung cancer patients with other illnesses.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am older than 18 years.I am a man who will use birth control during and 6 months after the study.I have another cancer, but it won't affect this trial's treatment.I have brain metastases but don't need steroids, had no recent brain radiation, and if on seizure meds, my condition is stable.I have HIV under control with medication, no recent severe infections, and my immune system is relatively strong.My cancer has spread to the lining of my brain and spinal cord.I still have side effects from cancer treatment, but only things like nerve pain, hair loss, or hormone issues.My lung cancer is at stage IV or stage III without options for a cure.I need special feeding methods due to stomach or bowel problems.I am on treatments for low calcium and my levels are now normal.Your corrected serum calcium level is higher than 12 mg/dl.I have had treatments for lung cancer before, regardless of how many.I can care for myself but may not be able to do heavy physical work.I have not had major surgery in the last 28 days and do not plan to during the trial.I do not have any uncontrolled illnesses that could interfere with the study.I don't need frequent procedures to remove excess fluid from my body.You are currently taking experimental drugs for cancer.I am only on targeted therapy or immunotherapy, not chemotherapy.I agree to use birth control during and for 6 months after the study.My treatment plan includes chemotherapy drugs like platinum or taxane.You need to have a measurable disease based on specific criteria.I have severe difficulty in performing daily activities and have liver or kidney problems.
- Group 1: Platinum doublet plus immunotherapy (IO)
- Group 2: Platinum doublet with or without a VEGFi
- Group 3: Single agent chemotherapy with or without a VEGFi
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what degree might Platinum doublet plus immunotherapy (IO) be detrimental to patients?
"A score of 2 was assigned to the Platinum doublet plus immunotherapy (IO) due to limited evidence demonstrating its safety, but no data supporting efficacy."
Is recruitment of participants ongoing for this experiment?
"Yes, the records on clinicaltrials.gov attest to this trial's ongoing recruitment status. It was initially posted by researchers in February 22nd of 2023 and recently updated in March 24th of the same year. They are aiming to acquire 280 participants from a single medical facility."
How many participants have signed up for this medical experiment?
"Yes, the information on clinicaltrials.gov confirms that this trial is actively enlisting patients. It was first listed on February 22nd 2023 and updated most recently on March 24th 2023. 280 people are needed to be recruited from 1 specified medical location."
Share this study with friends
Copy Link
Messenger